Living donor liver transplant for patients with colorectal cancer spread to the liver

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to establish a data registry that collects clinical, pathologic, and molecular data from patients with metastatic colorectal cancer who are undergoing living donor liver transplantation. The primary focus is on assessing overall survival and recurrence-free survival rates for these patients. By gathering comprehensive data, the study seeks to improve understanding of outcomes associated with this treatment approach. The observational nature of the study allows for real-world data collection without altering patient care.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age ≥ 18
* Non-amenable to curative hepatic resection as defined by FLR \<30%
* Histologically confirmed adenocarcinoma of the colon or rectum
* Candidate for LDLT for colorectal liver metastasis per the University of Rochester liver transplant program

Exclusion Criteria:

* Not a candidate of the LDLT liver transplant protocol for treatment of colorectal liver metastasis.
* Unwilling to consent

Where it's running

• University of Rochester Medical Center
  Rochester, New York, United States Recruiting

Study contacts

• Principal investigator: Roberto Hernandez-Alejandro, MD — University of Rochester
• Study coordinator: Roberto Hernandez-Alejandro, MD
• Email: roberto_hernandez@urmc.rochester.edu
• Phone: 585-275-5875

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Metastatic liver cancer patient registry from multiple Chinese centers

  This is a registry that collects real-world data on adults with liver metastases to understand patterns and prognosis and to support future research.

  Recruiting at 2 sites Anhui Provincial Hospital · Bengbu, Anhui and 2 other locations · NCT07602504

• Combination of balstilimab, botensilimab, and agenT-797 in pMMR colorectal cancer with liver metastases

  This trial tests whether a three-drug combination can help adults with metastatic, MSS colorectal cancer that has spread to the liver.

  Recruiting Phase 2 Scripps Health · La Jolla, California · NCT07550088

• Dual-target CAR-NK therapy for advanced colorectal cancer with CEA, GUCY2C, or HER2 markers

  This trial tests an off-the-shelf CAR-NK cell treatment that targets two tumor markers to see if it can shrink tumors in adults with advanced or metastatic colorectal cancer whose tumors express those markers.

  Recruiting Phase 1/2 Beijing Biotech · Shenzhen, Guangdong · NCT07462650

• COLONYVAQ™: personalized quantum‑classical neoantigen peptide vaccine combined with chemotherapy and nivolumab for MSS stage III colorectal cancer

  This trial will test a personalized neoantigen peptide vaccine guided by quantum‑classical AI together with standard oxaliplatin‑based chemotherapy and nivolumab in patients with completely resected, microsatellite‑stable stage III colorectal cancer.

  Recruiting Early Phase 1 Biogenea Pharmaceuticals Ltd. · Thessaloniki · NCT07328087

• ABT-301 with tislelizumab and bevacizumab for pMMR/non‑MSI‑H advanced or metastatic colorectal cancer

  This trial will test whether adding the oral drug ABT-301 to fixed-dose tislelizumab and bevacizumab is safe and tolerable for adults with pMMR/non‑MSI‑H locally advanced or metastatic colorectal cancer who have had at least two prior systemic therapies.

  Recruiting Phase 1/2 Anbogen Therapeutics, Inc. · Liverpool, New South Wales and 14 other locations · NCT07244705

• Second-line regorafenib for advanced RAS-mutant colorectal cancer

  This trial will test whether regorafenib given as a less-intensive, personalized second-line option can preserve quality of life and extend survival for people with RAS‑mutant metastatic colorectal cancer who had a long first-line benefit or have only one metastatic site.

  Recruiting Phase 2 National Cancer Institute, Naples · Naples, Italy · NCT07213570

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.